Laccetti, A. L., Smith, M. R., Scher, H. I., Nowfar, S., Einstein, D. J., Martin, B., Adorjan, P., Dissanayake, M., Verholen, F., Gao, X. (2026). Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.167